Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Asset Writedowns and Impairment (2021 - 2022)

Conmed (CNMD) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $899000.0 as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Asset Writedowns and Impairment changed N/A year-over-year to $899000.0, compared with a TTM value of $899000.0 through Dec 2022, changed N/A, and an annual FY2025 reading of $363000.0, changed N/A over the prior year.
  • Asset Writedowns and Impairment was $899000.0 for Q3 2021 at Conmed.
  • Across five years, Asset Writedowns and Impairment topped out at $899000.0 in Q3 2021 and bottomed at $899000.0 in Q3 2021.